Received: 6 August 2018
Accepted: 25 December 2018
First Online: 5 January 2019
Ethics approval and consent to participate
: The study was approved by the Partners Healthcare institutional review board. Waiver of individual patient informed consent was obtained due to minimal risk nature of the study.
: Not available.
: Ananthakrishnan has served on scientific advisory boards for Abbvie, Merck and Exact Sciences, and received research funding from Pfizer. Supported by a career development award from the American Gastroenterological Association and by grant K23 D099681 from the National Institute of Diabetes and Digestive and Kidney Diseases (H.K.); and by a career development award from the American Gastroenterological Association (K.S.) Khalili has received consulting fees from Abbvie, Inc., Samsung Bioepis, and Takeda Pharmaceuticals, and receives research funding from Takeda Pharmaceuticals; and Staller receives research funding from Takeda, Astra-Zeneca and Gelesis and consulting fees from Bayer Ag.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.